Cassava Sciences Stock News

Cassava Sciences Inc (SAVA) shares closed today 11.3% higher than it did at the end of yesterday. The stock is currently down 9.0% year-to-date, up 100.6% over the past 12 months, and up 934.5% over the past five years. Today, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.8%. Trading Activity Shares traded as high as $45.49 and as low as $36.51 this week.Shares closed 69.7% below its 52-week high and 132.8% above its 52-week low.Trading volume this week was 10.6% lower than the 10-day average and 38.6% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 3.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, beats it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 213.3% The company's stock price performance over the past 12 months beats the peer average by -809.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $39.45, marking a -1.42% move from the previous day.

As I pointed out in a previous discussion, short selling is not for the faint of heart and is probably best left to experienced traders. But there is an opportunity for investors to make money by keep

Take a wild ride -- but keep your position size small, please -- as SAVA stock could return to all-time highs or plummet to new depths soon. The post Cassava Sciences Is an Exciting Roll-the-Dice Biot

6 Top Biotech Ideas For 2022

Still, weighing risk against potential gains, the odds with SAVA stock may be on your side. If you are active in similar types of plays, consider it one to put on your watchlist.

Both Cassava Sciences and INmune Bio have brought impressive results on neuroinflammation and neurodegeneration. I expect INmune Bio's XPro to yield impressive results in its phase 2 trials like Cassa

Biogen (BIIB) stock declines after Medicare proposes covering FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in qualifying clinical studies.

These seven high risk stocks made wild moves in 2021, but still have the potential to rocket higher. All are full of both risk and reward.

It could be a make-or-break year for the clinical-stage biotech.

It could be a make-or-break year for the clinical-stage biotech.

I provide and compare historical data from the GameStop and AMC short squeezes that occurred last year to Cassava Sciences. The short squeeze for Cassava Sciences has already started – as was the ca

A key clinical trial, an enormous market opportunity, and breakthrough biotechnology could drive returns for shareholders this year.

Cassava Sciences could achieve 11x upside from the current price before FDA approval of Simufilam. Read what this means for SAVA stock here.

The market is pricing in an approximately 6% chance of FDA approval for Cassava Sciences' Alzheimer's small molecule pill, Simufilam. The distribution of 147,000 Simufilam to more than 250 Alzheimer's